Cancer Screening Test
Cancer is a leading cause of death worldwide, with millions of people affected each year. Cancers, especially those that are detected late in their stages are often deadly and cause problems for the patient and their families as well. Early detection is crucial for successful treatment and improved survival rates, but many cancers are not detected until they have already advanced. This is where the Galleria test for multi-cancer screening at early stages comes in.
The Galleria Test
The Galleria test is a new, non-invasive blood test that can detect multiple types of cancer at early stages. The test uses machine learning algorithms to analyze patterns in the DNA, looking for tiny fragments released by cancer cells into the bloodstream. These fragments are known as cell-free DNA (cfDNA) and can be used as a biomarker for cancer.
The Galleria test is designed to detect cancers that are typically difficult to diagnose at early stages. Cancers such as the pancreatic and ovarian cancers are often detected late and when they have grown beyond the point of recovery. It has been shown to be highly accurate, with a sensitivity of about 80 – 90% for stage 1 and 2 cancers.
Advantages of Galleria Test
One of the key advantages of the Galleria test is that it can detect multiple types of cancer in a single test. This is particularly important for people at high risk of developing cancer, such as those with a family history or genetic predisposition. Rather than having to undergo multiple tests for different types of cancer, the Galleria test can provide comprehensive screening in a single blood sample.
Another advantage of the Galleria test is that it is non-invasive, meaning that it does not require a tissue sample or biopsy. This makes it a more convenient and less risky option for patients, particularly those who may be hesitant to undergo more invasive procedures. All you need to do is come to us and give us a sample for your cancer screening in Phoenix, Arizona.
The Galleria test is still relatively new form of cancer screening. However, early studies have shown promising results, and it has already been approved for clinical use in some countries.
Benefits of Early Detection
The benefits of early detection cannot be overstated. By catching signs of cancer as soon as possible—sometimes even before they appear—we can treat them more effectively than if we waited until symptoms appeared or until the disease had progressed significantly. This means that our patients have better outcomes with fewer complications or side effects from treatments such as chemotherapy or radiation therapy. We also have time to develop customized treatment plans that are tailored specifically to each individual patient’s needs and goals.
Who should get the Galleria test?
The Galleria test is a type of genetic test that can help identify individuals who may have an increased risk of developing certain hereditary diseases. Typically, the test is recommended for people who have a family history of a particular genetic disorder, or who are concerned about their risk based on personal or medical factors. It may also be recommended for individuals who are planning to start a family and want to assess their risk of passing on a genetic disease to their children. Ultimately, the decision to undergo genetic testing is a personal one, and should be made in consultation with a healthcare professional who can provide guidance on the potential benefits and risks of the test.
Early cancer screening is an important aspect of health and well-being, and our practice is proud to offer the Galleria Test for patients looking for a comprehensive Cancer Screening experience. The Galleria Test is easy to remember – it screens for multiple types of cancers in their early stages, allowing the patient to take preventative steps if needed. Early detection of these cancers can be lifesaving, so remember to share it with those who might not need it but could benefit from the peace of mind! Our dedicated team can answer questions you may have about cancer screening at our Phoenix clinic.
- Pons-Belda OD, Fernandez-Uriarte A, Diamandis EP. Multi Cancer Early Detection by Using Circulating Tumor DNA-The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on “Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171″. Diagnostics (Basel). 2022;12(5):1244. Published 2022 May 17. doi:10.3390/diagnostics12051244
- Neal RD, Johnson P, Clarke CA, et al. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022;14(19):4818. Published 2022 Oct 1. doi:10.3390/cancers14194818